NASDAQ:LPTX - Leap Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.54 -0.06 (-0.70 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$8.60
Today's Range$8.46 - $8.66
52-Week Range$4.90 - $10.25
Volume15,500 shs
Average Volume103,568 shs
Market Capitalization$125.14 million
P/E Ratio-2.58
Dividend YieldN/A
Beta-0.16

About Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics logoLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. Its clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.

Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LPTX
CUSIPN/A
Phone617-714-0360

Debt

Debt-to-Equity RatioN/A
Current Ratio6.28
Quick Ratio6.28

Price-To-Earnings

Trailing P/E Ratio-2.58
Forward P/E Ratio-3.31
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.11 per share
Price / Book7.69

Profitability

EPS (Most Recent Fiscal Year)($3.31)
Net Income$-29,720,000.00
Net MarginsN/A
Return on Equity-182.53%
Return on Assets-96.58%

Miscellaneous

Employees22
Outstanding Shares14,500,000

Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics (NASDAQ:LPTX) released its earnings results on Friday, May, 11th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.24. View Leap Therapeutics' Earnings History.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Leap Therapeutics.

What price target have analysts set for LPTX?

1 brokerages have issued 12-month target prices for Leap Therapeutics' shares. Their forecasts range from $12.50 to $12.50. On average, they expect Leap Therapeutics' stock price to reach $12.50 in the next year. View Analyst Ratings for Leap Therapeutics.

What are Wall Street analysts saying about Leap Therapeutics stock?

Here are some recent quotes from research analysts about Leap Therapeutics stock:
  • 1. According to Zacks Investment Research, "Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. " (5/17/2018)
  • 2. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy Preclinical and clinical results highlights the effects of DKN-01 on the immune system. On April 16, Leap presented new results at the 2018 American Association for Cancer Research (AACR) Annual Conference that highlight the immunomodulatory effect of DKN-01 in preclinical tumor models. According to the latest results, DKN-01 is able to significantly alter the makeup of the tumor microenvironment (Exhibit 1), attract immune cells by inducing Cxcl10 expression (Exhibit 2), and improve the efficacy of PD-1 checkpoint inhibition (Exhibit 3)." (4/12/2018)

Who are some of Leap Therapeutics' key competitors?

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the folowing people:
  • Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 64)
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 49)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 62)
  • Dr. Cynthia A. Sirard M.D., Chief Medical Officer

Has Leap Therapeutics been receiving favorable news coverage?

News coverage about LPTX stock has trended somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Leap Therapeutics earned a daily sentiment score of 0.19 on Accern's scale. They also assigned news articles about the company an impact score of 45.52 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (2.95%), DAFNA Capital Management LLC (1.38%), JPMorgan Chase & Co. (0.28%), Point72 Asset Management L.P. (0.19%), Spark Investment Management LLC (0.12%) and Millennium Management LLC (0.09%). View Institutional Ownership Trends for Leap Therapeutics.

Which major investors are buying Leap Therapeutics stock?

LPTX stock was acquired by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., DAFNA Capital Management LLC, JPMorgan Chase & Co., Point72 Asset Management L.P., Spark Investment Management LLC and Millennium Management LLC. View Insider Buying and Selling for Leap Therapeutics.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $8.54.

How big of a company is Leap Therapeutics?

Leap Therapeutics has a market capitalization of $125.14 million. The company earns $-29,720,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis. Leap Therapeutics employs 22 workers across the globe.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.


MarketBeat Community Rating for Leap Therapeutics (LPTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Leap Therapeutics (NASDAQ:LPTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Leap Therapeutics in the last 12 months. Their average twelve-month price target is $12.50, suggesting that the stock has a possible upside of 46.37%. The high price target for LPTX is $12.50 and the low price target for LPTX is $12.50. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.672.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.50$12.50$15.50$15.50
Price Target Upside: 46.37% upside28.73% upside97.45% upside97.45% upside

Leap Therapeutics (NASDAQ:LPTX) Consensus Price Target History

Price Target History for Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics (NASDAQ:LPTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2018HC WainwrightInitiated CoverageBuy$12.50LowView Rating Details
3/7/2017Ladenburg ThalmannInitiated CoverageBuy ➝ Buy$18.00N/AView Rating Details
3/1/2017CitigroupInitiated CoverageMarket PerformN/AView Rating Details
2/28/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$13.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Leap Therapeutics (NASDAQ:LPTX) Earnings History and Estimates Chart

Earnings by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics (NASDAQ:LPTX) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.58 EPS
Next Year EPS Consensus Estimate: $-2.29 EPS

Leap Therapeutics (NASDAQ LPTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2018($0.48)N/AView Earnings Details
5/11/2018Q1 2018($0.61)($0.85)ViewN/AView Earnings Details
2/23/2018Q4 2017($0.77)($0.65)ViewN/AView Earnings Details
11/13/2017Q3 2017($0.6150)($0.73)ViewN/AView Earnings Details
8/11/2017Q2 2017($0.71)($0.74)ViewN/AView Earnings Details
5/12/2017Q1 2017($0.8650)($1.39)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Leap Therapeutics (NASDAQ:LPTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Leap Therapeutics (NASDAQ LPTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 58.70%
Institutional Ownership Percentage: 17.03%
Insider Trading History for Leap Therapeutics (NASDAQ:LPTX)
Institutional Ownership by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics (NASDAQ LPTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2017Augustine LawlorCOOBuy1,057,769$6.09$6,441,813.21View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Leap Therapeutics (NASDAQ LPTX) News Headlines

Source:
DateHeadline
Analysts Anticipate Leap Therapeutics (LPTX) to Post ($0.48) EPSAnalysts Anticipate Leap Therapeutics (LPTX) to Post ($0.48) EPS
www.americanbankingnews.com - May 23 at 9:18 PM
Zacks: Analysts Expect Leap Therapeutics (LPTX) to Post -$0.48 Earnings Per ShareZacks: Analysts Expect Leap Therapeutics (LPTX) to Post -$0.48 Earnings Per Share
www.americanbankingnews.com - May 18 at 1:43 PM
Leap Therapeutics (LPTX) Rating Lowered to Sell at Zacks Investment ResearchLeap Therapeutics (LPTX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 17 at 4:43 PM
Leap Therapeutics (LPTX) Upgraded at ValuEngineLeap Therapeutics (LPTX) Upgraded at ValuEngine
www.americanbankingnews.com - May 12 at 12:39 PM
Leap Therapeutics (LPTX) Releases  Earnings Results, Misses Expectations By $0.24 EPSLeap Therapeutics (LPTX) Releases Earnings Results, Misses Expectations By $0.24 EPS
www.americanbankingnews.com - May 12 at 12:10 PM
Why Leap Therapeutics (LPTX) Might Surprise This Earnings SeasonWhy Leap Therapeutics (LPTX) Might Surprise This Earnings Season
www.zacks.com - May 10 at 8:56 AM
Zacks: Leap Therapeutics (LPTX) Given $14.50 Consensus Target Price by AnalystsZacks: Leap Therapeutics (LPTX) Given $14.50 Consensus Target Price by Analysts
www.americanbankingnews.com - May 8 at 11:43 AM
Leap Therapeutics (LPTX) Lifted to Hold at ValuEngineLeap Therapeutics (LPTX) Lifted to Hold at ValuEngine
www.americanbankingnews.com - May 5 at 1:13 AM
Zacks: Brokerages Expect Leap Therapeutics (LPTX) Will Announce Earnings of -$0.49 Per ShareZacks: Brokerages Expect Leap Therapeutics (LPTX) Will Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - May 1 at 1:08 AM
Zacks: Leap Therapeutics (LPTX) Receives Consensus Recommendation of "Strong Buy" from AnalystsZacks: Leap Therapeutics (LPTX) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - April 23 at 5:15 AM
CLDX Disappoints Investors, ASNS Awaits Data In 2H18, BPMC Fails To Make A MarkCLDX Disappoints Investors, ASNS Awaits Data In 2H18, BPMC Fails To Make A Mark
www.nasdaq.com - April 17 at 9:07 AM
Leap Therapeutics (LPTX) Expected to Post Earnings of -$0.51 Per ShareLeap Therapeutics (LPTX) Expected to Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - April 14 at 1:09 AM
HC Wainwright Initiates Coverage on Leap Therapeutics (LPTX)HC Wainwright Initiates Coverage on Leap Therapeutics (LPTX)
www.americanbankingnews.com - April 12 at 10:51 AM
Vanda Pharmaceuticals (VNDA) versus Leap Therapeutics (LPTX) Head to Head ContrastVanda Pharmaceuticals (VNDA) versus Leap Therapeutics (LPTX) Head to Head Contrast
www.americanbankingnews.com - April 9 at 11:13 AM
Leap Therapeutics (LPTX) Stock Rating Lowered by Zacks Investment ResearchLeap Therapeutics (LPTX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 7 at 10:55 AM
Zacks: Leap Therapeutics Inc (LPTX) Given $15.50 Consensus Target Price by BrokeragesZacks: Leap Therapeutics Inc (LPTX) Given $15.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - April 7 at 9:55 AM
Leap Therapeutics (LPTX) Raised to Buy at Zacks Investment ResearchLeap Therapeutics (LPTX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:10 PM
Leap Therapeutics (LPTX) Cut to Hold at Zacks Investment ResearchLeap Therapeutics (LPTX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 30 at 8:24 PM
Leap Therapeutics (LPTX) Presents At Needham and Company 17th Annual Healthcare Conference - SlideshowLeap Therapeutics (LPTX) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 5:03 PM
Leap raises $16.1M in equity offeringLeap raises $16.1M in equity offering
seekingalpha.com - March 27 at 4:52 PM
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesLeap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - March 27 at 4:52 PM
Leap Therapeutics (LPTX) Upgraded to Buy by Zacks Investment ResearchLeap Therapeutics (LPTX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 26 at 10:24 PM
Leap Therapeutics prices public offering of common stockLeap Therapeutics prices public offering of common stock
seekingalpha.com - March 24 at 4:55 PM
Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common StockLeap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock
finance.yahoo.com - March 23 at 5:11 PM
Zacks: Analysts Set $15.50 Target Price for Leap Therapeutics Inc (LPTX)Zacks: Analysts Set $15.50 Target Price for Leap Therapeutics Inc (LPTX)
www.americanbankingnews.com - March 23 at 1:16 AM
Leap Therapeutics Announces Proposed Public Offering of Common StockLeap Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 22 at 5:10 PM
Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare ConferenceLeap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference
finance.yahoo.com - March 21 at 9:41 AM
Leap Therapeutics (LPTX) Provides DKN-01 Program Update and Announces Scientific Presentations at AACRLeap Therapeutics (LPTX) Provides DKN-01 Program Update and Announces Scientific Presentations at AACR
www.streetinsider.com - March 15 at 8:44 AM
Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual MeetingLeap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
finance.yahoo.com - March 15 at 8:44 AM
Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual MeetingLeap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
finance.yahoo.com - March 14 at 6:30 PM
Leap Therapeutics Inc (LPTX) Expected to Announce Earnings of -$0.51 Per ShareLeap Therapeutics Inc (LPTX) Expected to Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - March 10 at 9:20 PM
Zacks: Leap Therapeutics Inc (LPTX) Given Consensus Rating of "Buy" by AnalystsZacks: Leap Therapeutics Inc (LPTX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 8 at 9:29 PM
Zacks: Brokerages Set $15.50 Price Target for Leap Therapeutics Inc (LPTX)Zacks: Brokerages Set $15.50 Price Target for Leap Therapeutics Inc (LPTX)
www.americanbankingnews.com - February 27 at 1:24 PM
Zacks: Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 Earnings Per ShareZacks: Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 Earnings Per Share
www.americanbankingnews.com - February 22 at 3:14 AM
Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) EPSAnalysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) EPS
www.americanbankingnews.com - February 21 at 12:05 PM
Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) Earnings Per ShareAnalysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) Earnings Per Share
www.americanbankingnews.com - February 6 at 3:34 PM
Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor ConferenceLeap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:32 AM
Zacks: Leap Therapeutics Inc (LPTX) Given $15.50 Average Price Target by BrokeragesZacks: Leap Therapeutics Inc (LPTX) Given $15.50 Average Price Target by Brokerages
www.americanbankingnews.com - February 2 at 7:24 PM
Leap Therapeutics (LPTX) and Aeglea Bio Therapeutics (AGLE) Head-To-Head ComparisonLeap Therapeutics (LPTX) and Aeglea Bio Therapeutics (AGLE) Head-To-Head Comparison
www.americanbankingnews.com - February 2 at 1:18 AM
Leap Therapeutics (LPTX) and The Competition Head to Head AnalysisLeap Therapeutics (LPTX) and The Competition Head to Head Analysis
www.americanbankingnews.com - January 24 at 1:38 PM
Leap Therapeutics (LPTX) Downgraded by Zacks Investment ResearchLeap Therapeutics (LPTX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 21 at 12:32 AM
 Brokerages Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 EPS Brokerages Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 EPS
www.americanbankingnews.com - January 19 at 5:28 AM
 Brokerages Set $15.50 Price Target for Leap Therapeutics Inc (LPTX) Brokerages Set $15.50 Price Target for Leap Therapeutics Inc (LPTX)
www.americanbankingnews.com - January 18 at 3:06 AM
Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors TrialLeap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
finance.yahoo.com - January 16 at 9:23 AM
Head-To-Head Analysis: Leap Therapeutics (LPTX) & Its RivalsHead-To-Head Analysis: Leap Therapeutics (LPTX) & Its Rivals
www.americanbankingnews.com - January 15 at 9:16 PM
Leap Therapeutics (LPTX) Downgraded to "Hold" at Zacks Investment ResearchLeap Therapeutics (LPTX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 14 at 7:27 PM
 Leap Therapeutics Inc (LPTX) Given Average Rating of "Buy" by Brokerages Leap Therapeutics Inc (LPTX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 14 at 3:38 PM
Leap Therapeutics (LPTX) Upgraded by Zacks Investment Research to "Buy"Leap Therapeutics (LPTX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - January 9 at 6:08 AM
Leap Therapeutics (LPTX) & The Competition Head to Head ReviewLeap Therapeutics (LPTX) & The Competition Head to Head Review
www.americanbankingnews.com - January 2 at 9:14 PM
Contrasting Leap Therapeutics (LPTX) & Its PeersContrasting Leap Therapeutics (LPTX) & Its Peers
www.americanbankingnews.com - December 31 at 3:28 AM

SEC Filings

Leap Therapeutics (NASDAQ:LPTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Leap Therapeutics (NASDAQ:LPTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Leap Therapeutics (NASDAQ LPTX) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.